Adimab’s proprietary library design and presentation technologies enable the discovery of full-length human antibodies with broad epitope coverage and high affinity - faster than any known technology platform. By integrating all aspects of antibody discovery and developing sophisticated screening methods, Adimab rapidly selects high affinity human antibodies with improved formulation and manufacturing characteristics.